Literature DB >> 17390060

Biological comparison of ovarian cancer resistant cell lines to cisplatin and Taxol by two different administrations.

Xue-Dong Yan1, Min Li, Ye Yuan, Ning Mao, Ling-Ya Pan.   

Abstract

Drug resistance is one of the major obstacles to chemotherapy of ovarian cancer. Studies with cell lines can serve as an initial screen for agents that might modulate drug resistance. To establish more appropriate models of drug resistance and explore whether the differences exist in the different drug resistant sublines selected by different treatments, we induced SKOV3 cell line using cisplatin (CDDP) and Taxol over a period of 16 months by the pulse (SKOV3/CDDP-P and SKOV3/Taxol-P) and intermittent incremental (SKOV3/CDDP-80 and SKOV3/Taxol-25) method, respectively. The resistant phenotype of the four resistant sublines, SKOV3/CDDP-P, SKOV3/CDDP-80, SKOV3/Taxol-P and SKOV3/Taxol-25, was very stable and the resistance index was 4.12, 11.50, 261.98 and 622.76, respectively. In cell morphology, the cells from pulse treatment had remarkable changes compared with the cells from intermittent incremental treatment. SKOV3/CDDP-80 and SKOV3/Taxol-P grew more slowly than SKOV3/CDDP-P and SKOV3/Taxol-25. Multidrug resistance gene 1, multidrug resistance protein 1, lung resistance protein and glutathione S-transferase pi mRNA expression of SKOV3/CDDP-P and SKOV3/Taxol-25 had greater changes than that of SKOV3/CDDP-80 and SKOV3/Taxol-P. The results suggest there are great differences between the resistant cell lines resulting from pulse and intermittent incremental method. The resistant cells selected by the intermittent method were more resistant than the cells selected by the pulse method. The two resistant sublines selected by the pulse method may serve as appropriate models for the study of mechanisms of drug resistance in ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17390060

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  17 in total

1.  Tat-PTD-modified oncolytic adenovirus driven by the SCG3 promoter and ASH1 enhancer for neuroblastoma therapy.

Authors:  Chuan Jin; Di Yu; Matko Čančer; Berith Nilsson; Justyna Leja; Magnus Essand
Journal:  Hum Gene Ther       Date:  2013-08       Impact factor: 5.695

2.  Developing Clinically Relevant Acquired Chemoresistance Models in Epithelial Ovarian Cancer Cell Lines.

Authors:  Priti S Shenoy; Sourav Chakraborty; Snehal M Gaikwad; Asmita Sakpal; Pritha Ray
Journal:  Bio Protoc       Date:  2022-02-05

3.  Alteration of microRNA profiling in sphere-cultured ovarian carcinoma cells.

Authors:  Hwa Jun Cha; Sung Kwan An; Tae Jin Kim; Jae Ho Lee
Journal:  Oncol Lett       Date:  2018-05-25       Impact factor: 2.967

4.  Quantitative proteomic analysis of mitochondria from human ovarian cancer cells and their paclitaxel-resistant sublines.

Authors:  Ming Chen; Hong Huang; Haojie He; Wantao Ying; Xin Liu; Zhiqin Dai; Jie Yin; Ning Mao; Xiaohong Qian; Lingya Pan
Journal:  Cancer Sci       Date:  2015-07-24       Impact factor: 6.716

5.  Resistance to cisplatin and paclitaxel does not affect the sensitivity of human ovarian cancer cells to antiprogestin-induced cytotoxicity.

Authors:  Carlos D Gamarra-Luques; Maria B Hapon; Alicia A Goyeneche; Carlos M Telleria
Journal:  J Ovarian Res       Date:  2014-04-27       Impact factor: 4.234

6.  Epigenetic targeting drugs potentiate chemotherapeutic effects in solid tumor therapy.

Authors:  Jingjing Li; Dapeng Hao; Li Wang; Haitao Wang; Yuan Wang; Zhiqiang Zhao; Peipei Li; Chuxia Deng; Li-Jun Di
Journal:  Sci Rep       Date:  2017-06-22       Impact factor: 4.379

7.  The dynamic role of autophagy and MAPK signaling in determining cell fate under cisplatin stress in osteosarcoma cells.

Authors:  Sudeshna Mukherjee; Subhra Dash; K Lohitesh; Rajdeep Chowdhury
Journal:  PLoS One       Date:  2017-06-09       Impact factor: 3.240

8.  Specific Pyruvate Kinase M2 Inhibitor, Compound 3K, Induces Autophagic Cell Death through Disruption of the Glycolysis Pathway in Ovarian Cancer Cells.

Authors:  Jae Hyeon Park; Amit Kundu; Su Hyun Lee; ChunXue Jiang; Song Hee Lee; Ye Seul Kim; So Young Kyung; So Hyun Park; Hyung Sik Kim
Journal:  Int J Biol Sci       Date:  2021-05-05       Impact factor: 6.580

9.  Cell-cycle synchronization reverses Taxol resistance of human ovarian cancer cell lines.

Authors:  Xueqing Wang; Lingya Pan; Ning Mao; Lifang Sun; Xiangjuan Qin; Jie Yin
Journal:  Cancer Cell Int       Date:  2013-07-30       Impact factor: 5.722

10.  Common biological phenotypes characterize the acquisition of platinum-resistance in epithelial ovarian cancer cells.

Authors:  Maura Sonego; Ilenia Pellizzari; Alessandra Dall'Acqua; Eliana Pivetta; Ilaria Lorenzon; Sara Benevol; Riccardo Bomben; Paola Spessotto; Roberto Sorio; Valter Gattei; Barbara Belletti; Monica Schiappacassi; Gustavo Baldassarre
Journal:  Sci Rep       Date:  2017-08-02       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.